Log in to search using one of your social media accounts:

 

High Frequency of MTHFR, MTR and TC2 Gene Polymorphisms in Guatemalan Children with ALL
Methotrexate (MTX) is a key drug in ALL (ALL) treatment; it inhibits DNA replication by blocking the conversion of 5, 10 methylene tetrahydrofolate to 5-methylene tetrahydrofolate. MTX produces neurotoxicity. The methylene tetrahydrofolatereductase (MTHFR) (C677>T and A1298>C), methionine synthase (A2756G) and TC2 transcobalamin 2 (C776G) polymorphisms are associated with the MTX neurotoxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Claudia Carranza, Vanessa Zamora, Mariana Herrera, Luisa Rosales, Mauricio Villegas, Mariela Guerra, Nancy Escobar, Nely Marroqu ín, Claudia Osorio, Darwin Alvarez, Luis Alvarez Source Type: research

CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes
T Cell Receptor mimic (TCRm) antibodies to low-density peptide epitopes from undruggable intracellular proteins presented in the context of major histocompatibility (MHC) molecules are therapeutically effective in mouse models of human cancers. CD47 blockade by use of a high affinity SIRP α variant protein (CV1) has been shown to improve the effects of monoclonal antibodies to high-density antigens in tumor models by enhancement of antibody dependent cellular phagocytosis (ADCP). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Melissa Mathias, Jonathan Sockolosky, Aaron Chang, Cheng Liu, K. Garcia, David Scheinberg Source Type: research

Clofarabine Plus Cytarabine Therapy in Fludarabine Refractory Acute Leukemia Patients
Treatment alternatives are limited for patients that are relapse after or refractory to induction regimens for acute leukemia. FLAG regimen is combination therapy with fludarabine and cytarabine has been advocated as a potentially useful salvage regimen for the treatment of relapsed or refracory acute leukemia patients. But treatment of leukemia patients refractory after FLAG salvage regimen are very diffucult and complete remission rates are very low. Cloforabine is a new nucleoside analogue with high activity against leukemic blast. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Mehmet Dogu, Ismail Sari, Sibel Hacigoglu, Ali Keskin Source Type: research

Outcome of Adult Philadelphia Chromosome-Positive ALL in a Cancer Hospital in East India
Philadelphia chromosome (Ph)-positive ALL (ALL) is the most common cytogenetic abnormality in adult ALL. We retrospectively analyzed the outcome of newly diagnosed patients with Ph-positive ALL treated at our center between May 2011 and December 2015. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Saurabh Bhave, Anupam Chakrapani, Mayur Parihar, Neeraj Arora, Deepak Mishra, Reena Nair, Mammen Chandy Source Type: research

Propensity Score Analysis: Hyper-CVAD (HCVAD) + Ponatinib vs. HCVAD + Dasatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL)
The phase II of HCVAD + ponatinib achieved excellent outcome compared to that of HCVAD + dasatinib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Koji Sasaki, Elias Jabbour, Farhad Ravandi, Nicholas Short, Rita Khouri, Deborah Thomas, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Marina Konopleva, Nitin Jain, Ghayas Issa, Vicki Jeanis, Gal Moore, Rebecca Garris, Naveen Pemmaraju, Jorge Cortes, Source Type: research

Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study
A tyrosine kinase inhibitor (TKI) with combination of intensive chemotherapy achieves high response rate in the treatment of Ph+ ALL. Ponatinib is a more potent BCR-ABL inhibitor than other TKIs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Koji Sasaki, Hagop Kantarjian, Deborah Thomas, Farhad Ravandi, Maria Khouri, Jorge Cortes, Naveen Pemmaraju, Tapan Kadia, Nicholas Short, Ghayas Issa, Rebecca Garris, Gal Moore, Vicky Jeanis, Guillermo Garcia-Manero, Gautam Borthakur, William Wierda, Susa Source Type: research

Update Results of Frontline Therapy with Combination of Hyper-CMAD with Liposomal Vincristine (M) in Patients (Pts) with ALL (ALL)
Liposomal vincristine (M=Marqibo) has been approved as a salvage chemotherapy for pts with relapsed/refractory ALL. Replacement of regular vincristine with liposomal vincristine may lead to improve outcome with reduced neurotoxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Koji Sasaki, Elias Jabbour, Susan O'Brien, Maria Khouri, Deborah Thomas, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur, Nicholas Short, Ghayas Issa, Evguenia Gachimova, Rebecca Garris, Jorge Cortes, Hagop Kantarjian Source Type: research

Outcomes after Blinatumomab Failure in Patients with Relapsed/ Refractory (R/R) B-cell ALL (ALL)
The outcome of patients with R/R ALL post blinatumomab failure has not been thoroughly studied. Understanding the prognosis of the patients may guide clinicians to develop better treatment strategies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Musa Yilmaz, Hagop Kantarjian, Deborah Thomas, Tapan Kadia, Guillermo Garcia-Manero, Rita Khouri, Farhad Ravandi, Gautam Borthakur, Jorge Cortes, Alessandra Ferrajoli, Koji Sasaki, Jane Autry, Rebecca Garris, Kelsey Voit, Susan O ’Brien, Elias Jabbour Source Type: research

Prognostic Index and Nomogram for Overall Survival (OS) of Adult Patients with Philadelphia-negative B-cell ALL
A nomogram is a visual demonstration of a statistical model with scales for calculating the effect of weighted covariates on the probability of a specific outcome. In the literature, there is no available nomogram for ALL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Musa Yilmaz, Hagop Kantarjian, Xuemei Wang, Jorge Cortes, Garcia-Manero Garcia-Manero, Rita Khouri, Nicolas Short, Farhad Ravandi, Koji Sasaki, Marina Konopleva, Koichi Takahashi, William Wierda, Nitin Jain, Srdan Verstovsek, Zeev Estrov, Prithviraj Bose, Source Type: research

Utility of Day 14 Bone Marrow Evaluation in Adults with Philadelphia Chromosome-Negative ALL: Relationship with Minimal Residual Disease Status
The prognostic significance of Day 14 (D14) bone marrow (BM) assessment to detect increased blasts in patients undergoing induction for acute lymphoblastic leukemia (ALL) is not well-defined. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Nicholas Short, Hagop Kantarjian, Koji Sasaki, Maria Khouri, Jorge Cortes, Farhad Ravandi, Deborah Thomas, Guillermo Garcia-Manero, Issa Khouri, Partow Kebriaei, Richard Champlin, Sherry Pierce, Ghayas Issa, Marina Konopleva, Tapan Kadia, Carlos Bueso-Ram Source Type: research

Blinatumomab is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: the Bologna Compassionate Program Experience
Adult B-ALL patients still have a dismal prognosis. Safety and efficacy of blinatumomab, an anti CD3-CD19 Bite antibody, has been demonstrated both in MRD positive patients and in relapsed/refractory (R/R) setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Cristina Papayannidis, Stefania Paolini, Alessandra Santoro, Valentina Robustelli, Simona Soverini, Caterina De Benedittis, Enrica Imbrogno, Carolina Terragna, Andrea Ghelli Luserna di Rora, Sarah Parisi, Chiara Sartor, Giovanni Marconi, Silvia Lomonaco, Source Type: research

A Phase I/II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy as Frontline Therapy for Older Patients with ALL
The outcome of elderly patients with acute lymphoblastic leukemia (ALL) is poor. Combinations of novel agents, such as the anti-CD22 drug-antibody conjugate inotuzumab ozogamicin (INO), with reduced intensity chemotherapy may improve outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Nicholas Short, Elias Jabbour, Susan O'Brien, Rita Khouri, Farhad Ravandi, Deborah Thomas, Guillermo Garcia-Manero, Koji Sasaki, Gautam Borthakur, Nitin Jain, Marina Konopleva, Jovitta Jacob, Rebecca Garris, Jorge Cortes, Hagop Kantarjian Source Type: research

A Phase II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy for Patients with Relapsed/Refractory ALL
The outcome of patients with relapsed/refractory acute lymphoblastic leukemia (ALL) is poor. Combinations of novel agents, such as the anti-CD22 drug-antibody conjugate inotuzumab ozogamicin (INO), with reduced intensity chemotherapy may improve outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Nicholas Short, Elias Jabbour, Susan O'Brien, Koji Sasaki, Deborah Thomas, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur, Nitin Jain, Marina Konopleva, Jovitta Jacob, Rebecca Garris, Jorge Cortes, Hagop Kantarjian Source Type: research

Early Complete Response to Corticosteroids in T-Cell Acute Lymphoblastic Leukemia: Report of a Case and Review of the Literature
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant neoplasm of the bone marrow. It accounts for ∼20% of all cases of ALL. It is more common in adults than children, although the incidence diminishes in older age. Its clinical presentation usually includes hyperleukocytosis with extramedullary involvement, frequent central nervous system infiltration and the presence of a mediastinal mass. Mu tations of NOTCH1 and FBW7 are also frequent and are correlated with a better prognosis while the presence of RAS/PTEN is associated with a poor outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Danilo Tavares, Roberto Zani, Ilana Zalcberg, Glicinia Pimenta, Elias Jabbour, Daniel Tabak Source Type: research

Comparison of Vincristine Pharmacokinetics (PK) in Adolescent/Young Adult (AYA) Versus Younger Patients Defined by Tanner Stage during Treatment for Acute Lymphoblastic Leukemia (ALL)
Survival improvement in the AYA population has lagged behind that of younger patients. One contributing factor could be differences in drug metabolism and tolerance of cancer treatment. Previous studies have documented greater vincristine-related neurotoxicity (VRNT) in AYA vs. younger patients. One limitation of these studies is that age, rather than a more physiological assessment of developmental maturity, was used for the comparison. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Leidy Isenalumhe, Ashley Margol, Stan Louie, Michael Neely, Richard Sposto, Jemily Malvar, David Freyer Source Type: research

Metabolism of Membrane Phospholipids in Acute Leukemia and During Chemotherapy
Membranes of blood lymphocytes were characterized with the significant phylogenetically stabilized phospholipids-phospholipids interrelations. It is well known that abnormalities of these interrelations play an important negative role in the development of pathogenic mechanisms. The quantities and qualitative structure of phospholipids in the lymphocyte membranes, as well as lipids peroxidation processes and activity of phospholipase A2 have been studied in patients with acute leukemia and during of chemotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Yervand Hakobyan Tags: Acute Myelogenous Leukemia Source Type: research

Study of Alteration in Binding Affinity of RUNX1 with DNA because of Mutations Present in Acute Myeloid Leukemia Patients, and Change in its Direct/Indirect Gene Expression Level
To study the effect of two commonly known mutations i.e. K83E and R174Q in the binding of RUNX1 (involved in acute myeloid leukemia) with DNA and variation in gene expression level of its direct/indirect targeted genes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jyoti Zack, Daman Saluja Source Type: research

Clinical Impact of Underweight on the Outcome of Patients with Acute Myeloid Leukemia: Retrospective Study of JALSG AML201
Some recent studies have reported the impact of body-mass index (BMI) on the outcome of patients with acute myeloid leukemia (AML) in U.S. However, little is known about the impact of underweight on the outcome of adult patients with AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Kaito Harada, Noriko Doki, Takeshi Hagino, Shuichi Miyawaki, Shigeki Ohtake, Hitoshi Kiyoi, Yasushi Miyazaki, Hiroyuki Fujita, Noriko Usui, Hirokazu Okumura, Koichi Miyamura, Chiaki Nakaseko, Atsushi Fujieda, Tadashi Nagai, Takahisa Yamane, Hisashi Sakama Source Type: research

Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-SCT) with Post-Transplant Cyclophosphamide (Post-Cy) for Haematological Malignancies: A Single Centre Experience
Only 30% of patients have fully HLA-matched donor. In patients with urgent need to transplant, the use of alternative haploidentical donor is the only chance for cure. The introduction of post-transplant Cyclophosphamide (PT-Cy) GvHD prophylaxis allowed to decrease GvHD rate. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Dmitry Motorin, Renat Badaev, Andrey Zaritskey Source Type: research

Overall Survival (OS) of Older Patients with Acute Myeloid Leukemia (AML) and Association with Socioeconomic and Health Care System Factors
Non-biological factors may influence OS of older patients with AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Vijaya Bhatt, Baojiang Chen Source Type: research

Role of the Methylenetetrahydrofolate Reductase (MTHFR) A1982C Gene Polymorphism in Predicting Clinical Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantationin Patients with Myeloid Leukemia
Role of 5,10-methylenetetrahydrofolate reductase (MTHFR) A1298G polymorphism in Methotrexate Pharmacodynamics, used as GVHD prophylaxis, in myeloid leukemic patients undergoing HSCT is still uncertain. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Essam El Beih, Raafat Abdel-Fattah, Hosam Kamel, Mohamed Samra, Alaa El-Haddad, Omar Fahmy, Gamal Fathy, Gamal Ebid, Eman Radwan, Azza Kamel Source Type: research

Mechanisms of Resistance to Volasertib and Its Combination Effect with Azacitidine Inacute Myeloid Leukemia (AML)
Polo-like kinase1 (PLK1) plays a crucial role in many steps of mitosis. Since PLK1 is overexpressed in various cancer cells, it is thought to be a target for cancer therapy, volasertib, a selective Plk1 inhibitor, showed efficacy in clinical trials for elderly AML patients. However, its efficiency is limited in monotherapy and optimization of the combination therapies with other agents are under investigation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Yoshiya Adachi, Yuichi Ishikawa, Hitoshi Kiyoi Source Type: research

Comparison of the Modified Low-Dose Cytarabine with 5-Day Decitabine Therapy for Elderly AML Patients Unfit for Intensive Chemotherapy
Classical low-dose cytarabine (LDAC; ≤ 20 mg SQ BID for 10 days) remains a standard option for elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy, although long-term results were unsatisfactory. Recently, hypomethylating agents, such as decitabine and azacitidine, have been proved to have better outcomes t han the classical LDAC. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Byung Sik Cho, Seung-Hwan Shin, Jae-Ho Yoon, Yun-Ho Ko, Ki-Sung Eom, Hee-Je Kimi, Woo-Sung Min Source Type: research

A Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies
Outcomes are poor for older patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), or relapsed/refractory disease, and new therapies are needed. Using a chemosensitivity screening assay, we previously demonstrated that thioguanine/decitabine (TG-D) combinations can rescue therapeutic efficacy in primary leukemia cells isolated from patients with relapsed/refractory AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Daniel Lee, Todd Rosenblat, Mark Heaney, Joseph Jurcic, Azra Raza, Katherine Harwood, Ryan Shelton, Hakim Djaballah, Joseph Scandura, Anthony Letai, Mark Frattini Source Type: research

Clofarabine and Cytarabine Combination in Patients with Fludarabine/Cytarabine Refractory Acute Myeloid Leukemia
The long-term outcome of patients with relapsed/refractory acute myeloid leukemia (R/R-AML) is dismal and allogeneic hematopoietic cell transplantation (allo-HCT) seems to be the only curative treatment option for these patients. Patients who undergo allo-HCT in complete remission (CR) do benefit most from the procedure. Clofarabine in combination with cytarabine (CLARA) is an effective regimen in AML patients both in frontline and R/R settings. Here we report our multicenter, retrospective experience with CLARA in patients with fludarabine/cytarabine (FLA) refractory AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Emre Tekg ündüz, Ali Kaya, Sinem Bozdağ, Mehmet Doğu, Mehmet Dal, Filiz Bekdemir, Merih Kızıl, Hakan Sarı, Fevzi Altuntas Source Type: research

Single Institution Experience with G-CSF Mobilized T-Cell Replete Haploidentical Hematopoietic Cell Transplantation
The use of T-cell replete grafts from MHC-haploidentical donors, with post-transplant cyclophosphamide (PTCy) to deplete allo-reactive T cells as acute graft versus host disease (aGvHD) prophylaxis, is efficacious in patients without a matched sibling or timely access to a matched unrelated donor. Traditionally, bone marrow grafts are used to help reduce rates of aGvHD; however, using peripheral blood stem cells (PBSC) grafts in other settings is easier and associated with faster engraftment and decreased relapse rates. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Eric Huselton, Mike Slade, Rizwan Romee Source Type: research

Genomic Landscape of Acute Erythroid Leukemia
Acute erythroid leukemia (AEL) is an aggressive leukemia characterized by proliferation of erythroid and myeloid blast cells in the bone marrow that is of unknown pathogenesis and lacks effective therapies, especially in adults. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ilaria Iacobucci, Ji Wen, Manja Meggendorfer, Catherine Carmichael, John Choi, Yongjin Li, Katherine Masih, Debbie Payne-Turner, Daisuke Tomizawa, Nobutaka Kiyokawa, Laura Janke, Thomas Alexander, Giuseppe Basso, Franco Locatelli, Shirley Kow Yin Kham, Al Source Type: research

Comparative Value of Post-Remission Treatment in Cytogenetically Normal AML Subclassified by NPM1 and FLT3-ITD Allelic Ratio
Post-remission treatment (PRT) in patients with cytogenetically normal (CN)-AML in first complete remission (CR1) is debated. Molecular diagnostic analyses, including NPM1 and FLT3-ITD, provide additional prognostic information that may be used for a risk adapted approach. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jurjen Versluis, Florentien in 't Hout, Raynier Devillier, Wim van Putten, Markus Manz, Marie-Christiane Vekemans, Marie-Cecile Legdeur, Jakob Passweg, Johan Maertens, Jurgen Kuball, Bart Biemond, Peter Valk, Bert van der Reijden, Giovanna Meloni, Harry S Source Type: research

Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients
Retention of AML blasts in the bone marrow (BM), facilitated by CXCR4/CXCL12 interaction, protects AML cells from chemotherapy. BL-8040 (BKT140) is a high affinity CXCR4 inhibitor with long receptor occupancy. BL-8040's anti leukemic effect is mediated through robust leukemic blast mobilization, induction of leukemia cell differentiation and apoptosis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Gautam Borthakur, Martin Tallman, Yishai Ofran, James Foran, Geoffrey Uy, John DiPersio, Arnon Nagler, Jacob Rowe, Margaret Showel, Jessica Altman, Amnon Peled, Michal Abraham, Yaron Pereg, Abi Vainstein, Galia Oberkovitz, Tzipi Lustig, Arnon Aharon, Carl Source Type: research

Serum Ferritin Levels Prior to Transplantation Might be Used for Predicting the Severity of Transfusional Iron Overload in Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Recipients
Iron overload increases the risk of infections, veno-occlusive disease and hepatic dysfunction in post-transplant period. Our objective was to investigate the association of pre-transplant ferritin levels with complications and survival after allogeneic hematopoietic stem cell transplantation (alloHSCT). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Serdar Sivgin, Esen Karakus, Esra Yildizhan, Gokmen Zararsiz, Leylagul Kaynar, Bulent Eser, Mustafa Cetin, Ali Unal Source Type: research

Survival Comparison Amongst Commonly Used Frontline Regimens in Patients Age 70 Years and Older with Acute Myeloid Leukemia (AML): A Single-Institution Study of Over 600 Patients
Optimal frontline therapy for elderly patients with AML remains controversial. In this large, single-institution retrospective cohort study of AML patients over age 70, we present survival analysis and comparison amongst a variety of commonly used regimens. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Varun Dhulipala, Martine Extermann, Najla Al Ali, Jongphil Kim, Marina Sehovic, Tea Reljic, Benjamin Djulbegovic, Jeffrey Lancet Source Type: research

Outcome of Allogeneic Hematopoietic Stem Cell Transplant in Therapy Related Myeloid Neoplasms: Comparative Study with a De Novo Myeloid Neoplasms Group
Therapy related myeloid neoplasms (t-MN) are associated with worse prognosis, resulting in a more complex therapeutic approach and a lack of an accepted standard therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Oscar Ferre Bermejo, Estefania P érez, Oriana López-Godino, José María Bastida, Luis García-Martín, Felix López-Cadenas, Nerea Arratibel, Monica Baile, Alvaro Veiga, Dolores Caballero, Monica Cabrero Source Type: research

Relevance of Molecular Monitoring of Transcript Level in RUNX1-RUNX1T1 AML
Molecular breakpoint level fluctuations monitoring during AML treatment and subsequent follow-up may have role in prognosis and improve treatment decisions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Larisa Girshova, Ekaterina Ovsyannikova, Konstantin Bogdanov, Sergey Kuzin, Andrey Zaritskey Source Type: research

Mutant NPM1 MRD and FLT3-ITD Status are Independent Prognostic Factors for the Risk of Relapse in AML Patients
Recent studies reported the prognostic relevance of measurable residual disease (MRD) after induction chemotherapy in AML patients with mutated NPM1 (mNPM1mrd). However, the predictive value of FLT3-internal tandem duplication (ITD) status at diagnosis in the context of mNPM1mrd remains controversial. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Tim Grob, Rosa Meijer, Fran çois Kavelaars, Mario Bargetzi, Carlos Graux, Markus Manz, Thomas Pabst, Jakob Passweg, Marie-Christiane Vekemans, Gert Ossenkoppele, Bob Löwenberg, Peter Valk, Mojca Jongen-Lavrencic Source Type: research

Up-Regulation of Regulatory T Cells, CD200 and TIM3 Expression in Acute Myeloid Leukemia (AML)
AML cells could evade immune control with AML microenvironment is immunosuppressive and anti-apoptotic favoring the survival of malignant hematopoietic cells. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Asmaa Zahran, Mona Sayed, Mostafa Mohammed Saleh Source Type: research

Prognostic Value of Regulatory T Cells, CD200 and TIM3 Expression in Acute Myeloid Leukemia (AML)
AML employ a number of immune evasion mechanisms which inhibit the generation or functional execution of anti-tumor immune responses that could contribute to disease resistance. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Asmaa Zahran, Mona Sayed, Mostafa Mohammed Saleh Source Type: research

5-year Experience of Oral Deferasirox (Exjade) Use Prior to Transplantation in Patients with Iron Overload that Underwent Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): Retrospective Analysis of a Single Center from Turkey
Iron overload (IO) is considered an important cause of mortality and morbidity in patients who undergo allogeneic hematopoietic stem cell transplantation (alloHSCT). Iron chelation is critical in patients with IO prior to transplantation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Serdar Sivgin, Esra Yildizhan, Neslihan Sanli, Leylagul Kaynar, Gokmen Zararsiz, Bulent Eser, Mustafa Cetin, Ali Unal Source Type: research

Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant
Concomitant NPM1 and FLT3 mutation occurs in 20% of AML patients. Molecular response and achievement of negative minimal residual disease (MRD) are strong predictors of long-term outcome. However, little is known about the dynamics of molecular response in NPM-1 and FLT-3 double positive mutations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Rana Salem, Radwan Massoud, Rami Mahfouz, Ali Bazarbachi, Jean El Cheikh Source Type: research

Outcomes of Relapsed Core Binding Factor Acute Myeloid Leukemia: an MD Anderson Experience
CBF-AML, which accounts for ∼20% of AML, is defined by presence of t(8;21)(q22;q22) [t(8;21)] and inv(16)(p13q22) or t(16;16)(p13;q22) [inv(16)]. Although CBF-AML is considered a favorable cytogenetic subset, many patients experience relapse, and it is critical to identify features that can predict patient outcomes after rel apse. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Maliha Khan, Jorge Cortes, Wei Qiao, Mohanad Alzubaidi, Sherry Pierce, Rebacca Slack, Farhad Ravandi, Hagop Kantarjian, Gautam Borthakur Source Type: research

ARV-825, a BRD4 Inhibitor, Leads to Sustained Degradation of BRD4 with Broad Activity Against Acute Myeloid Leukemia and Overcomes Stroma Mediated Resistance by Modulating Chemokine Receptor, Cell Adhesion and Metabolic Targets
BRD4, a member of the bromodomain and extra terminal domain (BET) family, is critical in the assembly of a ‘super enhancer complex’ driving expression of oncogenes MYC, SOX2 and NF-KB and anti-apoptotic proteins e.g. Bcl-2 and BCL-XL and validated target in AML therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sujan Piya, Philip Lorenzi, Teresa McQueen, Eric Davis, Yimin Qian, Michael Andreeff, Gautam Borthakur Source Type: research

Gemtuzumab Ozogamicin Produces Durable Responses in Variant Acute Promyelocytic Leukemia with t(11;17)
We present two patients with t(11;17) APL successfully treated with GO. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Asha Balakrishnan, Kendra Sweet, Rami Komrokji, David Sallman, Eric Padron, Alan List, Jeffrey Lancet Source Type: research

Impact of Persistent Somatic Mutations on Day 14 After Induction Chemotherapy for Acute Myeloid Leukemia
Residual AML on D14 after induction typically warrants re-induction. This decision is based on D14 cellularity and blast count, yet many with aplastic D14 marrows fail to achieve CR. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Kendra Sweet, Mohammad Hussaini, Jeffrey Lancet, Rami Komrokji, Alan List, Lynn Moscinski, Jinming Song, Eric Padron Source Type: research

Andrographolide Pre-treatment Enhances the Anti-tumor Activity of Topotecan on Acute Myeloid Leukemia Cells In Vitro
Topotecan (TP) is an anticancer drug currently being used in the treatment of several cancer types including leukemia. However, due to its dose-limiting cytotoxicity, combination treatments have been investigated to achieve better outcome with less side effects. Andrographolide (AG) is a plant-derived compound that was reported to induce apoptosis and autophagy in acute myeloid leukemia cell lines. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sandra Rizk, Sarah Abi Raad, Achraf Jardaly, Annalise Zouein, Paola Ghanem, Mohammad Hodroj Source Type: research

The Importance of CD200 in Differential Diagnosis of Chronic Lymphocytic Leukemia (CLL) and Possible Role of CD200 in Existence of Infection Complications
CLL is common hematological malignancy among Armenian population. 62 patients with the suspect of lymphoid neoplasm were admitted to Hematology Center of Armenia during last 2 years. The diagnosis was based on morphological, immunophenotyping, cytogenetic and FISH methods. All CLL cases had different clinical courses which were depend on clinical stage and accompanying infection complications. 32 of these patients had infection complications mainly in form of recurrent pneumonia. As the clinical features and phenotype of CLL are very similar to Mantle cell Lymphoma (MCL), CD200 was added to standard immunophenotyping panel...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Aline Aywaz, Anna Sevoyan, Smbat Daghbashyan Source Type: research

Stimulation of the B-Cell Receptor (BCR) Induces Tyrosine Phosphorylation of STAT3 via NF- κB Dependent Mechanism
Whereas in CLL cells phosphorylation of STAT3 on serine 727 residues is constitutive, phosphorylation of STAT3 on tyrosine 705 residues is inducible. However, IL-6 induces tyrosine pSTAT3 phosphorylation within 15 minutes and IgM induces pSTAT3 within 2 to 4h. Like STAT3, the transcription factor NF- κB is constitutively activate in CLL cells. Because IL-6 is an NF-κB-target we wondered whether prolonged stimulation with IgM antibodies induces tyrosine pSTAT3 via NF-κB-mediated induction of IL-6 in CLL cells. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Uri Rozovski, David Harris, Ping Li, Zhiming Liu, Alessandra Ferrajoli, Burger Jan, Philip Thompson, William Wierda, Preetesh Jain, Michael Keating, Zeev Estrov Source Type: research

A 51 Year Old Man with Hypogammaglobulinemia Secondary to Chronic Lymphocytic Leukemia Receiving fSCIG in the Home Setting
We present a man with hypogammaglobulinemia secondary to CLL who received monthly fSCIG replacement treatments. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Michelle Greer, Leslie Vaughan, Elissa Ritt Source Type: research

Update on Efficacy and Tolerability of Ofatumumab as Front-Line Treatment for Patients with CLL that are Elderly and Have Severe Co-Morbidities and/or Other Malignancies
Elderly individuals with chronic lymphocytic leukemia (CLL) often present with multiple comorbidities and other cancers. Current therapy for these patients is largely based on targeted agents and/or monoclonal antibodies without chemotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Lorenzo Falchi, Candida Vitale, Maria Ciccone, Christina Hinojosa, Michael Keating, Naveen Pemmaraju, William Wierda, Gautham Borthakur, Jan Burger, Alessandra Ferrajoli Source Type: research

The CXCR4 Downstream Signaling Pathways in Chronic Lymphocytic Leukemia: a Target to Reverse Microenvironment Protection
Chronic lymphocytic leukemia (CLL) cells are protected from spontaneous and fludarabine-induced cell death by tumor microenvironment through the CXCL12/CXCR4 axis. The binding of CXCR4 to CXCL12 activates Ras/ERK1-2/Akt and RhoA-dependent signalling pathways. We have recently described the activation of Ras/ERK1-2 and RhoA/RhoA kinase signalling, the upregulation of the pro-survival factor Akt, and the increase in the activity of the transcription factor HIF-1 α in CLL cells co-cultured with stromal cells (SC). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Candida Vitale, Valentina Griggio, Maria Todaro, Chiara Riganti, Iris Chiara Salaroglio, Chiara Salvetti, Micol Rigoni, Myriam Foglietta, Barbara Castella, Mario Bocacdoro, Massimo Massaia, Marta Coscia Source Type: research

Genetic Landscape and Gene Expression Profile of Chronic Lymphocytic Leukemia Patients with Ultra-Stable Disease
Chronic lymphocytic leukemia (CLL) shows a highly heterogeneous clinical course. Characterizing ultra-stable (US) CLL might help in elucidating the bases of CLL stability/progression. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ilaria Del Giudice, Sara Raponi, Marilisa Marinelli, Jiguang Wang, Luciana Cafforio, Caterina Ilari, Monica Messina, Silvia Bonina, Simona Tavolaro, Mykola Bordyuh, Francesca Romana Mauro, Sabina Chiaretti, Davide Rossi, Gianluca Gaidano, Anna Guarini, Ra Source Type: research

Outcomes with Ibrutinib by Line of Therapy in Patients with CLL: Analyses from Phase 3 Data
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase, is indicated by the US FDA for the treatment of patients with CLL/small lymphocytic lymphoma, and allows for treatment without chemotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Nishitha Reddy, Susan O'Brien, John Byrd, Peter Hillmen, Steven Coutre, Jennifer Brown, Paul Barr, Jacqueline Barrientos, Stephen Devereux, Tadeusz Robak, Thomas Kipps, Alessandra Tedeschi, Florence Cymbalista, Paolo Ghia, Stephen Chang, Joi Ninomoto, Dan Source Type: research